Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation
- PMID: 23100275
- PMCID: PMC5490471
- DOI: 10.3324/haematol.2012.073601
Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation
Abstract
Anticoagulation by a standard dosage of an inhibitor of thrombin generation presupposes predictable pharmacokinetics and pharmacodynamics of the anticoagulant. We determined the inter-individual variation of the effect on thrombin generation of a fixed concentration of direct and antithrombin-mediated inhibitors of thrombin and factor Xa. Thrombin generation was determined by calibrated automated thrombinography in platelet-poor plasma from 44 apparently healthy subjects which was spiked with fixed concentrations of otamixaban, melagatran, unfractionated heparin, dermatan sulfate and pentasaccharide. The variability of the inhibitory effect of the different anticoagulants within the population was determined using the coefficient of variation, i.e. the standard deviation expressed as a percentage of the mean. The inter-individual coefficients of variation of the endogenous thrombin potential and peak height before inhibition were 18% and 16%, respectively and became 20%-24% and 24%-43% after inhibition. The average inhibition of endogenous thrombin potential and peak height (ETP, peak) brought about by the anticoagulants was respectively: otamixaban (27%, 83%), melagatran (56%, 63%), unfractionated heparin (43%, 58%), dermatan sulfate (68%, 57%) and pentasaccharide (25%, 67%). This study demonstrates that the addition of a fixed concentration of any type of anticoagulant tested causes an inhibition that is highly variable from one individual to another. In this respect there is no difference between direct inhibitors of thrombin and factor Xa and heparin(-like) inhibitors acting on the same factors.
Figures


Similar articles
-
Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats.Eur J Pharmacol. 2012 Jul 5;686(1-3):74-80. doi: 10.1016/j.ejphar.2012.04.031. Epub 2012 Apr 21. Eur J Pharmacol. 2012. PMID: 22546231
-
Old versus new anticoagulants: focus on pharmacology.Recent Pat Cardiovasc Drug Discov. 2010 Jun;5(2):120-37. doi: 10.2174/157489010791515269. Recent Pat Cardiovasc Drug Discov. 2010. PMID: 20337579 Review.
-
The importance of thrombin inhibition for the expression of the anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulphate.Br J Haematol. 1985 Aug;60(4):695-704. doi: 10.1111/j.1365-2141.1985.tb07474.x. Br J Haematol. 1985. PMID: 2411283
-
Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist.Thromb Res. 2000 Sep 15;99(6):603-12. doi: 10.1016/s0049-3848(00)00276-0. Thromb Res. 2000. PMID: 10974347
-
Heparin cofactor II and other endogenous factors in the mediation of the antithrombotic and anticoagulant effects of heparin and dermatan sulfate.Semin Thromb Hemost. 1985 Apr;11(2):133-7. doi: 10.1055/s-2007-1004370. Semin Thromb Hemost. 1985. PMID: 3898370 Review. No abstract available.
Cited by
-
Heparins: A Shift of Paradigm.Front Med (Lausanne). 2019 Nov 15;6:254. doi: 10.3389/fmed.2019.00254. eCollection 2019. Front Med (Lausanne). 2019. PMID: 31803745 Free PMC article.
-
Manufacture and Initial Characterisation of RAPIDTM Biodynamic Haematogel, an Autologous Platelet and Leukocyte-Rich Plasma Gel for Diabetic Foot Ulcers.Gels. 2024 Sep 2;10(9):572. doi: 10.3390/gels10090572. Gels. 2024. PMID: 39330174 Free PMC article.
-
Bioimpedance Analysis as Early Predictor for Clot Formation Inside a Blood-Perfused Test Chamber: Proof of Concept Using an In Vitro Test-Circuit.Biosensors (Basel). 2023 Mar 17;13(3):394. doi: 10.3390/bios13030394. Biosensors (Basel). 2023. PMID: 36979606 Free PMC article.
-
Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram.Res Pract Thromb Haemost. 2021 Mar 11;5(3):439-446. doi: 10.1002/rth2.12497. eCollection 2021 Mar. Res Pract Thromb Haemost. 2021. PMID: 33870029 Free PMC article.
-
A comparison of anti-coagulation monitoring tests in ICU patients receiving a continuous infusion of unfractionated heparin.Crit Care Resusc. 2024 Nov 21;26(4):255-261. doi: 10.1016/j.ccrj.2024.08.004. eCollection 2024 Dec. Crit Care Resusc. 2024. PMID: 39781492 Free PMC article. No abstract available.
References
-
- Bauer KA. New anticoagulants: anti IIa vs anti Xa - is one better? J Thromb Thrombolysis. 2006;21(1):67-72. - PubMed
-
- Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med.2009;361(24):2342-52. - PubMed
-
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91. - PubMed
-
- Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12):1139-51. - PubMed
-
- Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365(11):981-92. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical